Quarterly ResultAug 13, 2026, 06:12 AM
Evotec H1 Revenue Down 19.2% to €300.1M; FY Outlook Lowered
AI Summary
Evotec SE announced its second quarter and first half 2026 results, reporting a 19.2% decrease in H1 Group revenues to €300.1 million and an Adjusted Group EBITDA loss of €42.7 million. The company updated its full-year 2026 outlook, lowering revenue expectations to €570-610 million and Adjusted Group EBITDA to a loss of €70-105 million, primarily due to shifts in partnership timing and lower revenue conversion. Despite challenging market conditions and significant net losses, Evotec highlighted growing commercial momentum in D&PD and Just – Evotec Biologics, and confirmed that its 'Horizon' transformation initiative is on track to deliver cost savings.
Key Highlights
- Evotec updated FY 2026 outlook: Group revenues expected €570-610M, Adjusted Group EBITDA €(70)-(105)M.
- H1 2026 Group revenues decreased 19.2% to €300.1M (6M 2025: €371.2M).
- H1 2026 Adjusted Group EBITDA was a loss of €42.7M (6M 2025: loss of €1.9M).
- H1 2026 net loss totaled €168.6M (6M 2025: loss of €75.1M).
- D&PD net sales excluding strategic partnerships increased 28% year-on-year in H1 2026.
- Just – Evotec Biologics revenue decreased 29.3% to €72.3M in H1 2026.
- Reorganization costs of €98.9M were incurred in H1 2026 for Project Horizon.
- Proceeds of €89.3M were received from the disposal of Tubulis GmbH.
Price Impact
More from EVO